ExonHit Announces Final Terms for RedPath Acquisition

The deal, which may be worth up to $32 million, includes an upfront payment of $12.5 million in cash, and up to $19.5 million in stock.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.